PFM Health Sciences’s Alexion Pharmaceuticals ALXN Stock Holding History

PFM Health Sciences’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-300,000	Closed	-$46.9M	–	112
2020 Q4	$46.9M	Buy	+300,000	New	+$38.6M	1.65%	21

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

PFM Health Sciences's ALXN Position: Q3 2021 in Review

PFM Health Sciences sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 901,441 shares — an estimated $166M sold.

PFM Health Sciences first reported a position in ALXN in Q4 2014 and held it in 10 quarters. The position peaked at $166M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

PFM Health Sciences reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
PFM Health Sciences sold 901,441 Alexion Pharmaceuticals shares in Q3 2021, an estimated $166M.
PFM Health Sciences first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 10 quarters.
PFM Health Sciences's Alexion Pharmaceuticals position peaked at $166M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on PFM Health Sciences's 13F filing for Q3 2021, filed 15 Nov 2021.